SEKISUI DIAGNOSTICS (UK) LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -6.4%

  £26,121,949 → £24,451,608

• Cash

  +8.5%

  £2,440,401 → £2,648,562

• Net assets

  -7.2%

  £63,837,564 → £59,251,788

• Employees

  +8.1%

  124 → 134

• Operating profit

  -11.6%

  -£5,825,792 → -£6,499,523

• Profit before tax

  -20%

  -£4,987,136 → -£5,984,699

• Wages

  +3.9%

  £6,943,772 → £7,213,810

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101 Reduced Disclosure Framework

Reporting scope

Standalone (parent only)

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Under both the base case and the severe but plausible downside scenario, the forecasts indicate that the company will have sufficient liquidity to continue to settle its liabilities as they fall due for a period of at least 12 months from the date of approval of the financial statements. Consequently, the Directors believe it is appropriate to continue to prepare the financial statements on a going concern basis.”

Group structure

1. SEKISUI DIAGNOSTICS (UK) LIMITED · parent
   1. Sekisui Diagnostics GmbH 100% · Germany · sales and distribution of chemical reagents

Significant events

• “The loss for the year after taxation amounted to £4,585,776 (year ended 31 March 2024 loss of £4,070,916). The results reflect a combination of reduction in requirements of some Diagnostics Enzyme products and demand growth from some Diagnostic Enzyme customers which is impacting mix and profitability of the Enzyme business, which is being addressed through pricing and cost control measures.”
• “We are part way through a budgeted significant investment (£20M) to enable us to grow our Biopharma CDMO (Contract Development and Manufacturing Organisation) business. R&D and QC labs have been completed and are occupied and the main part of the investment (£18.5M) in a Bio Pharma production facility is partially completed and expected to be commissioned, validated and operational in FY26.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.